Science
My aim is to produce mathematical models that will ultimately help oncologists optimize anticancer therapies. I am particularly interested in myeloid dysplastic syndrome (MDS), chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). In collaboration with Dr. Yogen Saunthararajah of the Cleveland Clinic, a major focus of my current research is on the use of low chronic doses of the nucleoside analog decitabine as a differentiaion therapy for MDS and AML. With respect to CML, DNA damage mediated by oxidative stress in the chronic phase of CML is now also on my radar.